Fig. 4From: An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspectiveHospitalization and overall HCRU costs at 18 months. ARTA, androgen receptor-targeted agent; HCRU, healthcare resource utilization. The number correspond to a cohort of 100 patients for each treatmentBack to article page